Saturday 17 October 2026 Export UNBX’s income statement to Excel — free account

UNITY Biotechnology, Inc.

UNITY Biotechnology, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $236,000.00. In the quarter to March 2025, EPS fell 26.5% and free cash flow fell 23.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.06 0.00 0.00%

Follow UNBX

Alert me

Market cap: $3.4M
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: n/a
Altman Z: −5.56
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 7.06%

Capital & Financial Ratios $m

Market Cap 3.44

Revenue —

Net Income (27.50)

Free Cash Flow (22.04)

Net Debt (16.93)

Current Ratio 1.95

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (0.44)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 42.86%

Next Y EPS Growth 11.36%

Next Y revenue growth 3,754.24%

Next 5Y EPS Growth 40.77%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2022	2023	2024	Q'25
Cash	95	43	23	17
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	97	47	24	18

	2022	2023	2024	Q'25
Payables	2	1	1	2
ST’ Debt	9	—	—	—
Other	—	—	—	—
	20	8	9	9

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(44.26%)	(52.23%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	—	0	—	—	0
’21	—	—	—	5	5

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	—	—	—	—
’24	(5)	(5)	(5)	(6)	(21)
’23	(11)	(11)	(7)	(8)	(37)
’22	(15)	(15)	(11)	(12)	(52)
’21	(15)	(13)	(12)	(5)	(45)
’20	(25)	(19)	(17)	(17)	(78)
’19	(21)	(19)	(17)	(16)	(72)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	—	—	—	—
’24	(5)	(5)	(5)	(6)	(21)
’23	(11)	(11)	(7)	(7)	(37)
’22	(15)	(15)	(11)	(12)	(52)
’21	(15)	(13)	(12)	(5)	(45)
’20	(25)	(20)	(17)	(17)	(79)
’19	(21)	(20)	(17)	(16)	(74)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.43)	—	—	—	—
’24	(0.34)	(0.31)	(0.38)	(0.50)	(1.54)
’23	(0.37)	(0.85)	(1.05)	(0.28)	(2.70)
’22	(2.80)	(1.90)	(1.36)	(1.00)	(4.68)
’21	(2.90)	(3.20)	(3.00)	(1.80)	(10.90)
’20	(5.90)	(3.80)	(5.20)	(3.70)	(18.40)
’19	(4.40)	(5.60)	(5.10)	(3.90)	(18.80)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	—	—	103.30	56.10	27.20	12.30	2.09	1.46	0.94	Analyst estimates 2025–2027 Powerpack
	High	—	—	—	245.60	168.70	154.40	97.80	19.11	5.72	2.02
People
People	Employees	—	—	—	106	98	61	65	32	19	16
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.07	0.01	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	1	—	—	—	5	0	—	—
	Gross margin, %	—	0.00	100.00	0.00	0.00	0.00	100.00	100.00	—	—
	EBT	—	(30)	(45)	(76)	(82)	(94)	(61)	(44)	(40)	(26)
	EBT margin, %	—	0.00	(3,231.26)	0.00	0.00	0.00	(1,269.34)	(18,842.80)	0.00	0.00
	Net income	—	(30)	(45)	(76)	(82)	(94)	(61)	(44)	(40)	(26)
	Depreciation	—	0	1	1	2	7	5	3	6	3
Per share, $
Per share, $	Revenue	—	0.00	4.32	0.00	0.00	0.00	0.86	0.02	0.00	0.00
	Earnings	—	(114.17)	(139.64)	(27.00)	(18.80)	(18.40)	(10.90)	(4.68)	(2.70)	(1.54)
	Cash flow	—	(61.58)	(119.94)	(20.03)	(16.60)	(15.40)	(8.07)	(5.52)	(2.51)	(1.24)
	Capex	—	(8.43)	(5.28)	(0.45)	(0.36)	(0.13)	(0.03)	0.03	0.01	0.00
	Free cash flow	—	(70.00)	(125.23)	(20.48)	(16.96)	(15.53)	(8.11)	(5.49)	(2.50)	(1.24)
	Book value	—	0.00	284.06	56.84	27.67	16.30	10.67	5.91	1.92	0.39
	Shares, m	—	0	0	3	4	5	6	9	15	17
Valuation, ×
Valuation, ×	P/E	—	—	0.00	—	—	—	0.00	0.00	—	—
	P/S	—	—	0.00	—	—	—	0.00	0.00	—	—
	P/B	—	—	0.00	—	—	—	1.37	0.50	—	—
	EV/Sales	—	—	0.00	—	—	—	0.00	0.00	—	—
	EV/FCF	—	—	1.75	—	—	—	(0.33)	0.89	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(16)	(38)	(57)	(72)	(78)	(45)	(52)	(37)	(21)
	Capex	—	(2)	(2)	(1)	(2)	(1)	0	0	0	0
	Free cash flow	—	(19)	(40)	(58)	(74)	(79)	(45)	(52)	(37)	(21)
Balance, $m
Balance, $m	Working capital	—	90	81	156	112	86	74	77	39	15
	Total debt	—	—	0	0	0	29	21	20	—	—
	Net debt	—	(89)	(86)	(171)	(122)	(69)	(67)	(74)	(43)	(23)
	Shareholders’ equity	—	—	91	161	121	83	60	56	28	6
Returns, %
Returns, %	ROA	—	(30.55)	(87.54)	(53.92)	(49.42)	(61.03)	(43.22)	(35.71)	(41.95)	(50.29)
	ROIC	—	0.00	(628.56)	0.00	0.00	(413.16)	0.00	0.00	0.00	0.00
	ROE	—	48.94	71.77	(196.95)	(58.41)	(92.19)	(85.26)	(76.90)	(94.36)	(148.97)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Jun 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ERNA Ernexa Therapeutics Inc.	$3.5M	— (loss-making)	— (loss-making)	−94.12% (below 0%: shrinking)	n/m	−64.10% (below 0%: shrinking)	100.00%	0.00%	Compare
PPCB Propanc Biopharma Inc	$3.5M	— (loss-making)	—	—	−99.64% (below 0%: shrinking)	−1,637.42% (below 0%: shrinking)	—	0.00%	Compare
CVKD Cadrenal Therapeutics, Inc.	$3.5M	— (loss-making)	—	—	n/m	+26.24% (above 0%: growing)	0.00%	0.00%	Compare
IOBTQ IO Biotech, Inc.	$3.5M	— (loss-making)	—	—	n/m	+11.22% (above 0%: growing)	0.00%	0.00%	Compare
UNBX UNITY Biotechnology, Inc.	$3.4M	— (loss-making)	— (loss-making)	—	n/m	−23.10% (below 0%: shrinking)	0.00%	0.00%
LIPO Lipella Pharmaceuticals Inc.	$3.4M	— (loss-making)	— (loss-making)	−36.44% (below 0%: shrinking)	n/m	−41.79% (below 0%: shrinking)	100.00%	0.00%	Compare
PBLA Panbela Therapeutics Inc.	$3.4M	— (loss-making)	—	—	n/m	+66.23% (above 0%: growing)	—	0.00%	Compare
CMND Clearmind Medicine Inc.	$3.3M	— (loss-making)	—	—	n/m	−77.94% (below 0%: shrinking)	0.00%	0.00%	Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR	$3.2M	— (loss-making)	— (loss-making)	−100.78% (below 0%: shrinking)	n/m	−2.73% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$3.4M	—	—	−94.12%	—	−22.26%	50.00%	0.00%

All 614 Biotechnology stocks →

UNITY Biotechnology, Inc. (UNBX) key facts

UNITY Biotechnology, Inc. (UNBX) is a Biotechnology company in the Healthcare sector.
UNITY Biotechnology, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $236,000.00.
As of October 14, 2025, UNBX traded at $0.06, a market capitalization of $3.4 million.
Return on equity was −149.0% and debt-to-equity 0.00.
Its Altman Z-score is −5.56 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.